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Abstract
Perinatal hypoxic–ischaemic encephalopathy (HIE) occurs in
1–2 in every 1000 term infants and the devastating conse-
quences range from cerebral palsy, epilepsy and neurological
deficit to death. Cellular damage post insult occurs after a
delay and is mediated by a secondary neural energy failure.
AMP-activated protein kinase (AMPK) is a sensor of cellular
stress resulting from ATP depletion and/or calcium dysregu-
lation, hallmarks of the neuronal cell death observed after HIE.
AMPK activation has been implicated in the models of adult
ischaemic injury but, as yet, there have been no studies
defining its role in neonatal asphyxia. Here, we find that in
an in vivo model of neonatal hypoxia–ischaemic and in
oxygen/glucose deprivation in neurons, there is pathological
activation of the calcium/calmodulin-dependent protein kinase
kinase b (CaMKKb)-AMPKa1 signalling pathway. Pharmaco-
logical inhibition of AMPK during the insult promotes neuronal
survival but, conversely, inhibiting AMPK activity prior to the
insult sensitizes neurons, exacerbating cell death. Our data
have pathological relevance for neonatal HIE as prior sensi-
tization such as exposure to bacterial infection (reported to
reduce AMPK activity) produces a significant increase in
injury.
Keywords: AMPK, hypoxia, ischaemia, neonatal, oxygen–
glucose deprivation.
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Moderate-to-severe hypoxic–ischaemic encephalopathy
(HIE), caused by a lack of oxygen or blood flow to the
brain around the time of birth, affects 1–2 babies in every
1000 in the UK and far more in the developing world
(Kurinczuk et al. 2010). The consequences for infants and
parents affected by HIE are devastating; 15–20% will die in
the post-natal period and a further 25% will develop severe
and long-lasting neurological impairments. Currently, ther-
apeutic hypothermia is the only available treatment and,
although not successful in all cases, will double the chance of
normal survival (Azzopardi et al. 2014). However, the
success of therapeutic hypothermia provides proof-of-con-
cept that intervention post injury can be effective.
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It is now well accepted that although there is some brain
damage during HIE, the majority of cell death occurs after a
delay as a result of a secondary neural energy failure
(Azzopardi et al. 1989; Lorek et al. 1994; Blumberg et al.
1997; Gilland et al. 1998). AMP-activated protein kinase
(AMPK) is a sensor of cellular stress, activated by
phosphorylation by one of two upstream kinases, Liver
Kinase B1 (LKB1) or calcium/calmodulin-dependent protein
kinase kinase b (CaMKKb), in response to depletion of ATP
or alterations in intracellular calcium concentrations (Carling
et al. 2008; Steinberg and Kemp 2009). AMPK is a
heterotrimer consisting of a catalytic (a1 or a2) subunit,
coupled to two regulatory subunits (b1 or b2; and c1, c2 or
c3). Maximal activation of AMPK is achieved by phosphor-
ylation at threonine 172 within the a subunit, allosteric
activation by AMP and inhibition of dephosphorylation by
ADP at nucleotide-binding sites on the c subunit (Xiao et al.
2007, 2011). Once activated, AMPK shuts down ATP
consuming, anabolic pathways and promotes ATP-generat-
ing, catabolic pathways (Steinberg and Kemp 2009). As
such, many metabolic substrates have been identified
including regulators of fatty acid and cholesterol synthesis,
mitochondrial biogenesis and protein synthesis. Therefore,
AMPK has become a potential therapeutic target because of
its role in diseases which have perturbation in energy
homeostasis such as type 2 diabetes, cancer and inflamma-
tion (Carling et al. 2012; Hardie 2013).
Compared with peripheral tissues, the role of AMPK in the
brain is still being delineated. Neurons have small energy
stores but high energy demands and activation of AMPK can
occur in response to a number of pathologically relevant
stresses such as glucose deprivation (Culmsee et al. 2001),
hypoxia (Gusarova et al. 2011; Mungai et al. 2011) and
excitotoxicity (Weisova et al. 2009; Concannon et al. 2010).
Increasingly, AMPK activation is implicated in the develop-
ment of neurological disorders (Ju et al. 2011; Vingtdeux
et al. 2011; Lim et al. 2012; Mochel et al. 2012), although
as with the neuronal studies, it is unclear whether this
activation is beneficial (Chen et al. 2009; Choi et al. 2013)
or deleterious (McCullough et al. 2005; Li et al. 2007;
Vingtdeux et al. 2010).
The majority of studies of AMPK in the mechanism of
hypoxic–ischaemic injury have utilized adult middle cerebral
artery occlusion (MCAO) models of stroke (Li et al. 2010;
Choi et al. 2013; Jin et al. 2014; Venna et al. 2014).
However, it is increasingly clear that such results cannot be
easily translated into the neonatal brain environment and
many mechanisms of cell death are different in the immature
versus the adult brain (Ferriero 2004; Vannucci and Hagberg
2004; Wang et al. 2009, 2010; Hagberg et al. 2014). It
therefore becomes very relevant to investigate specific
mechanisms in appropriate neonatal models.
In this study, we examine the contribution of AMPK
activation to the development of hypoxic–ischaemic brain
injury in neonatal mouse brain. We find that AMPK activity
is up-regulated during the injury but quickly returns to
baseline levels on removal of the insult. In an in vitro model
of hypoxia–ischaemia (HI) in primary neurons, activation of
AMPK during the injury results in increased cell death,
whereas inhibition of AMPK during the insult protects the
cells, implicating AMPK in the injury process. Conversely,
we find that inhibition of AMPK prior to injury sensitizes
neurons to subsequent insult. Taken together, these data
show a dual role of AMPK in HI brain injury in neonates
depending on whether it is modulated prior or during the
insult.
Materials and methods
Materials
Unless otherwise stated, all reagents were purchased from Sigma-
Aldrich (Dorset, UK) with cell culture medium and supplements
from Life Technologies (Paisley, UK).
In vivo model of HI
Experiments were conducted in Sweden under the guidance of
the Swedish Ethical Authorization of Gothenburg University
(Jordbruksverket, J€onk€oping, Sweden). Animals were bred in-
house and pups of both sexes used for the injury model. Post-natal
day (P)9 C57/Bl6 mice were subjected to left common carotid
artery ligation followed by 50 min of hypoxia in a 10% oxygen
environment stabilized at 36°C (Rice et al. 1981; Vannucci and
Vannucci 1997; Hedtjarn et al. 2002). At various time points
during and after the insult, animals were quickly decapitated and
the head snap frozen in liquid nitrogen to avoid artifactual
activation of AMPK. Brains were dissected in a cryostat (20°C)
to isolate and harvest hippocampus, cortex and striatum. For brain
damage assessment, animals were killed by overdose of anaesthetic
(pentobarbital) and perfused with saline (Baxter, Newbury, UK)
for 5 min followed by a perfusion fixation with Histofix. After
various dehydration steps, brains were paraffin embedded and cut
in coronal section of 6 lm. Brain damage was assessed by
microtubule-associated protein 2 immunohistochemistry of the
ipsi- and contralateral hemispheres on coronal sections as
described previously (Jarlestedt et al. 2013).
Preparation of primary neurons
Animal use was in accordance with local rules (King’s College,
London) and with the regulations and guidance issued under the
Animals (Scientific Procedures) Act (1986). CaMKKb-deficient
primary neurons were prepared from animals kindly donated by Prof
K. P. Giese (KCL) and wild-type neurons were prepared from time-
mated dams purchased from Charles River Laboratories Inc.,
Harlow, UK. Pregnant C57/Bl6 mice were killed by schedule 1 at
13.5–14.5 days of gestation and embryonic cortical neurons
prepared as described previously (Thornton et al. 2011). Cells were
plated at a density of 2 9 106 cells/6 cm plate and propagated for a
minimum of 9 days in vitro (DIV) before treatments were applied.
Arabinocytidine (5 lM) was added once at DIV 2–4 to prevent
propagation of dividing cells and ensure the purity of the neuronal
culture.
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In vitro oxygen–glucose deprivation
At DIV 10–12, neurons were subjected to oxygen–glucose depri-
vation (OGD) in neurobasal-A medium lacking glucose and
incubated in a hypoxia chamber (Billups-Rothenburg Inc. Del
Mar, CA, USA) filled with an anoxic atmosphere of 5% CO2
balanced in nitrogen at 37°C for 2 h. Cells were incubated with 5-
aminoimidazole-4-carboxamide 1-b-D-ribofuranoside a precursor for
ZMP, an AMP mimetic (AICAR; 2 mM), the calcium ionophore
ionomycin (an activator of CaMKKb; 2 lM final concentration), or
the CaMKKb inhibitor STO609 (10 lg/mL), all from Tocris
Bioscience, Bristol, UK. Pharmacological modulators were incu-
bated with the cells either during OGD (OGD experiments), or for
2 h at 3 h or 24 h prior to OGD (pre-treatment experiment). Culture
medium was assayed for release of lactate dehydrogenase (LDH)
(described below), and cell lysates prepared in ice-cold HEPES
Buffer A (50 mM HEPES (pH 7.5), 50 mM sodium fluoride, 5 mM
sodium pyrophosphate, 1 mM EDTA, +1 9 protease inhibitors)
containing 1% (v/v) Triton X-100.
Caspase 3/7 activity measurements
Primary neurons were subjected to OGD and measurement of active
caspases (3/7) post insult determined at time points from 0 to 30 h
using the CellEvent Caspase 3/7 Green peptide (2 lM final
concentration, Life Technologies) in accordance with manufacturer’s
instructions. Hoechst stain (2 lg/mL) was also included in the
media. After incubation, cells were washed and fluorescence
determined at 530 nm (caspase 3/7) and 460 nm (Hoechst) on a
platereader (GloMax Multi+; Promega, Southampton, UK.). Back-
ground fluorescence measurements were removed and the ratio of
caspase fluorescence per cell number calculated. Data were normal-
ized to a non-OGD control and compared with the 0-h time point.
LDH assay
Cell death was assessed using an LDH cytotoxicity kit (Sigma,
Dorset, UK) in accordance with manufacturer’s instructions. LDH
released into the medium was used to measure cell membrane
permeability and therefore act as a surrogate for cell death. LDH
concentrations were determined by absorbance at 450 nm (Glomax;
Promega) and normalized for background absorbance at 750 nm
and medium-alone controls.
AMPK activity
Immunoprecipitation of AMPK subunits and assay of activity by
incorporation of radiolabelled MgATP into a substrate peptide has
been described previously (Woods et al. 1996; Thornton et al.
2011).
Western blots
Proteins were resolved on 10–12% (w/v) NuPAGE BisTris gels in
3-(N-morpholino)propanesulfonic acid buffer (Life Technologies)
and transferred to polyvinylidene fluoride membrane. Proteins were
analysed by western blot using the following antibodies: phospho-
acetyl-CoA carboxylase, AMPKa (pT172) and AMPKb (all at
1 : 1000; Cell Signaling Technology, Beverly, MA, USA).
Analysis of mRNA by qRT-PCR
For preparation of total RNA, primary neurons were harvested in
TRIzol (1 mL per 1 9 106 cells; Life Technologies), and total
RNA was extracted in chloroform as per manufacturer’s instruc-
tions. The resulting RNA was purified using an RNeasy column
(Qiagen, Manchester, UK) and eluted in DNase/RNase-free dH2O.
Total RNA (200 ng) was analysed using Taqman gene expression
assays and RNA-to-CT kit (Life Technologies) on a StepOneplus
Cycler (Life Technologies). Data were normalized to the expression
of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and to
controls using the delta-delta CT method (Livak and Schmittgen
2001). Primer pairs used in the study are as follows: GAPDH
(Mm99999915), AMPKa1 (Prkaa1, Mm01296700), AMPKa2
(Prkaa2, Mm01264789) from Life Technologies.
Statistics
Results are expressed as means  SEM from three or more
independent experiments. Statistical analysis was performed using
Prism (GraphPad Software Inc., San Diego, CA, USA). Statistical
significance between two conditions was established with a two-
tailed Student’s t-test, whereas significance among multiple datasets
was determined by ANOVA, followed by post-hoc Bonferroni
multiple comparison tests. Results were considered significant at
p < 0.05.
Results
AMPK is activated early in development
To establish a baseline of activation for AMPK in our
animals, we assessed activity at different developmental
stages from P5 to P21. Our data show that AMPK activation
is not homogeneous within the brain during development.
Both brain region and time had a significant effect on the
variation in AMPK activity and in addition, post-hoc analysis
revealed a significant difference in AMPK activity between
hippocampus and cortex at P5 (Fig. 1a). However, as
previously suggested (Saito et al., 2009), we found that
there was an overall decrease in AMPK activity in the mouse
brain during this period (Fig. 1a).
AMPK is activated in vivo in response to hypoxic–ischaemic
insult
To test our hypothesis that, considering the large energy
failures associated with HI, AMPK should be activated, we
measured AMPK activity on HI injured and uninjured mice.
We subjected P9 mice to HI insult using the well-character-
ized Vannucci model (Rice et al. 1981; Vannucci and
Vannucci 1997); the insult generated approximately 25%
tissue loss localized to the hippocampus, cortex and striatum
(Figure S1). As expected, we observed a rapid increase in
AMPK activity in these three ipsilateral areas during the HI
insult compared with equivalent contralateral regions
although the maximal kinase activity occurred at slightly
different times in the different regions. Remarkably, this
activation quickly returned to baseline levels once the
animals were returned to normoxia (Fig. 1b). These data
provide in vivo confirmation that up-regulation of AMPK
activity is involved in neonatal HI.
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AMPK is activated in primary neurons in response to
oxygen–glucose deprivation
To further investigate the role of AMPK during HI, we
generated primary cortical neurons from E14.5 mice and
subjected them to an in vitro OGD insult for 90 min. The
activation of cell death mechanisms was confirmed by the
appearance of active caspase 3 which began at 2 h post insult
and was sustained for at least 24 h (Fig. 2a). A dissection of
the timeline of AMPK activation during and after the insult
revealed that AMPK activity increased rapidly during the
insult, reaching a peak at 60 min (Fig. 2b). Interestingly, the
activation died away rapidly post insult when the cells were
returned to normoxia and complete medium (Fig. 2b)
correlating with our in vivo observations. As might be
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Fig. 1 AMPK is activated during hypoxic–
ischaemic injury in vivo. (a) Protein samples
from hippocampus (black bars), striatum
(grey bars) and cortex (white bars) were
generated from snap-frozen, uninjured
mouse brains at the times indicated and
AMPK activity measured. Significant
differences were observed with respect to
brain region (a, p = 0.0031) and age of
animal (b, p = 0.0001). Post hoc tests
revealed that AMPK activity was initially
significantly higher in the hippocampus
(*p < 0.05) than the cortex but activity in
all three regions declined as the animal
aged (n = 6–7). (b) Brain samples from
sham-injured (triangles) and hypoxia–
ischaemia (HI)-injured (squares) mice were
taken at times indicated either during the
insult itself or during the recovery phase.
Protein lysates from the hippocampus (top
graph), striatum (middle graph) and cortex
(bottom graph) were prepared and AMPK
assayed as above. AMPK is activated in
vivo during HI (*p < 0.05, **p < 0.01) but
returns to baseline during recovery (n = 6–
7).
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expected, AMPK activation resulted in phosphorylation of
acetyl-CoA carboxylase, a well-characterized substrate of
AMPK (Fig. 2c).
AMPK activation during OGD is mediated by the CaMKKb-
AMPKa1 pathway
Previous studies suggested that in an adult (MCAO) stroke
model infarct volume was determined by the activation of
AMPKa2 complexes (Li et al. 2007, 2010). However, more
recently, it has been suggested that hypoxic stress acts
through calcium influx, triggering CaMKKb-mediated
AMPKa1 activation (Gusarova et al. 2011; Mungai et al.
2011). We therefore isolated AMPKa1- or AMPKa2-specific
immune complexes from neuronal lysates prepared at various
time points during OGD and found that the changes in
AMPK activity were largely mediated by AMPKa1
(Fig. 3a). Moreover, analysis of OGD lysates from WT
and CaMKKb-deficient primary neurons found that although
there was increases in AMPK activity in both lysates at
5 min (presumably because of depletion of ATP), this was
not maintained in the CaMKKb-deficient neurons at 30 min
(Fig. 3b). This suggests that in our model, OGD up-regulates
AMPKa1 complex activity via activation of CaMKKb.
Prolonged activation of AMPK is detrimental in the neuronal
response to oxygen–glucose deprivation
A number of pharmacological agents are capable of modi-
fying AMPK activity. As our results implicated a CaMKKb-
AMPKa1-dependent pathway, we used our previously
characterized system of ionomycin (activator)/STO609
(inhibitor) treatment to modulate AMPK activity in a
CaMKKb-dependent manner (Thornton et al. 2008). We
exposed neurons to OGD in the presence of ionomycin or
STO609 to determine the effect of extreme activation or
inhibition of AMPK on cell survival. As expected, STO609
significantly reduced AMPK activity during OGD (Fig. 4a).
Conversely, AMPK appeared to be maximally activated by
OGD alone, as no further increase in the magnitude of
activation was observed on addition of ionomycin. However,
OGD in the presence of ionomycin resulted in a more rapid
(15 min) and sustained (> 1 h) AMPK activation (Fig. 4a).
To determine the effect on cell survival, we incubated
primary neurons with ionomycin or STO609 and measured
release of LDH into the medium as a surrogate for cell death.
Neither ionomycin nor STO609 alone altered neuronal
survival (Fig. 4b); however, in combination, the prolonged
activation of AMPK by ionomycin during OGD significantly
increased cell death after the insult, whereas STO609
inhibition of AMPK had the opposite effect, increasing cell
survival (Fig. 4c). To confirm that it was indeed the
activation of AMPK and not just calcium dysfunction
causing the changes in neuronal survival, we repeated the
experiment using a calcium-independent, classical activator
of AMPK, AICAR, a precursor for ZMP, an AMP mimetic.
AICAR treatment did not alter cell survival alone (Fig. 4d);
however, although not significant, there was a trend towards
increased LDH release, in a similar manner to that evoked by
ionomycin (Fig. 4e). These data suggest that acute AMPK
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Fig. 2 AMPK is activated in primary neurons during oxygen–glucose
deprivation (OGD). Primary neurons were subjected to OGD for 90 min
followed by a return to normoxia and complete medium. (a) Primary
neurons were incubated in the presence of a fluorescent caspase 3
activity probe. Fluorescence was measured at the time points
indicated, normalized to number of cells and expressed as fold change
compared with a non-OGD control. Caspase activity at 24 h was
significantly greater than that measured at 0 h (n = 3; *p < 0.05). (b)
Protein lysates were prepared at time points during the insult and
subsequent recovery and assayed for AMPK activity. AMPK activity
rapidly increased, peaking at 60 min before returning to baseline
during recovery (**p < 0.01, ***p < 0.001, ****p < 0.0001; n = 4). (c)
Protein lysates prepared at 0 and 24 h post insult were analysed by
western blot for active AMPK (p-AMPK) and phosphorylated acetyl-
CoA carboxylase (p-ACC), an AMPK substrate. Blots were controlled
for total AMPK expression using an antibody recognizing the ubiqui-
tous AMPK-b regulatory subunits (AMPK-b; n = 3). Phosphorylation of
ACC confirms up-regulation of functional AMPK activity during the
insult.
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activation in response to OGD is detrimental to the survival
of the neurons and suggests that targeting AMPK activation
in the acute phase of injury may be beneficial.
Decreasing AMPK prior to injury sensitizes neurons to OGD
Classical preconditioning is a paradigm in which a sublethal
stress (e.g. mild OGD) is evoked prior to the onset of lethal
injury (e.g. severe OGD). This sublethal exposure renders
cells more resistance to injury and has been used successfully
in neonatal rat models of HI (Gidday et al. 1994; Gustavsson
et al. 2005). As the previous experiment demonstrated that
sustained AMPK activity during OGD was detrimental, we
sought to examine if pre-treatment using AMPK modulators
would protect the neurons from OGD. We exposed primary
neurons to ionomycin or STO609 for 2 h and the cells were
then allowed a 3-h recovery before exposure to OGD. Cell
survival was measured immediately after the insult and
revealed that in neurons pre-treated with STO609, OGD-
induced cell death was greatly exacerbated (Fig. 5a).
Surprisingly, pre-treatment with ionomycin did not signifi-
cantly alter the cells’ response to OGD, although there
seemed to be a trend towards protection (Fig. 5a). As the
preincubation may take time to exert its effects, we repeated
the experiment with a 24 h recovery time between the
exposure and OGD. We observed a similar pattern as for 3 h;
however, any changes in cell survival did not reach
significance (Fig. 5b). One possibility for the altered behav-
iour of STO609 may be that as a consequence of prolonged
inhibition, AMPK expression is up-regulated in compensa-
tion and from our previous results, increased AMPK during
OGD is deleterious (Fig. 4c). To rule out such homeostatic
responses, we analysed the mRNA expression of AMPKa1
and AMPKa2 at 3 h and 24 h post treatment with AMPK
modulators. We found that although both subunits were
expressed at similar levels in neurons (Figure S2), there were
no alterations in expression of either subunit in response to
treatment or recovery time (Fig. 5c). Taken together, these
data imply that inhibition of AMPK just prior to insult may
sensitize neurons to HI injury, potentially through down-
regulation of AMPK activation-mediated metabolic path-
ways.
Discussion
AMPK is known for its role as energy sensor of the cell,
working to restore energy balance by inhibiting energy-
consuming pathways and promoting energy-producing path-
ways. It is now well recognized that HIE is associated with
energy failure which correlates with delayed onset of injury.
Our aim was to investigate the role of AMPK in the
development of injury in vivo in HI models and in vitro in
OGD.
Our results show that AMPK is rapidly activated both in
vivo and in vitro. Prolonging the activation of AMPK during
the insult results in increased cell death, suggesting that
AMPK may contribute to the development of injury. This is
borne out by the opposite experiment in which inhibition of
AMPK activity during the insult confers significant protec-
tion. In non-neuronal tissue, activation of AMPK is meta-
bolically advantageous, preserving and restoring ATP levels,
regulating glucose uptake, promoting autophagy and mito-
chondrial biogenesis (Ruderman et al. 2013). However, there
is still controversy surrounding prolonged AMPK activity in
the brain. AMPK promotes whole body energy homeostasis
balancing hormone peptide signalling in the hypothalamus
(Xue and Kahn 2006). In addition, activation of AMPK
modulates excitotoxic glutamatergic signalling (Culmsee
et al. 2001; Kuramoto et al. 2007). Longer term, potentially
pathological activation of AMPK may occur during neuro-
degenerative disorders (Alzheimer’s disease, Huntington’s
disease) in which there is an early but prolonged perturbation
of energy metabolism (Chou et al. 2005; Vingtdeux et al.
2011; Lim et al. 2012). At a cellular level, elegant studies in
primary cerebellar granule neurons identified a role for
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Fig. 3 AMPK activation during oxygen–glucose deprivation (OGD) is
mediated by the CaMKKb-AMPKa1 pathway. Wild-type (WT) and/or
CaMKKb-deficient (CaMKKb/) primary neurons were subjected to
OGD for 5 min or 30 min and protein lysates prepared. (a) AMPKa1-
(closed circles) or AMPKa2-specific immune complexes (open circles)
were isolated from OGD-treated WT neurons and assayed for activity
compared with untreated controls. There was a striking difference
observed in that the majority of AMPK activity was attributed to
AMPKa1-containing complexes (n = 2). (b) AMPK activity was
assessed in WT and CaMKKb-deficient neurons subjected to OGD.
The absence of CaMKKb prevented full AMPK activation at 30 min
(***p < 0.001; n = 3–6).
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AMPK in response to transient glutamate excitation. This
excitation resulted in a glucose-dependent hyperpolarization
of the mitochondrial membrane potential and activation of
AMPK, facilitating the membrane localization of glucose
transporter GLUT3 and providing neuronal tolerance
(Weisova et al. 2012). This mechanism seems to underlie
the protective properties of the Alzheimer’s and Huntington’s
disease drug Laterpirdine/Dimebon, which can also activate
AMPK, promote GLUT3 translocation and protect neurons
from glutamate excitotoxicity (Weisova et al. 2013). How-
ever, the same group also suggests that prolonged activation
of AMPK in neurons in response to a variety of stimuli is
reported to up-regulate the expression of pro-apoptotic Bim
leading to cell death (Concannon et al. 2010). Our results are
consistent with this latter view in that prolonged AMPK
activation was detrimental to cell survival when combined
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Fig. 4 Prolonged activation of AMPK during oxygen–glucose depri-
vation (OGD) increases cell death. Primary neurons were subjected to
OGD for 2 h either alone or in the presence of the calcium/calmodulin-
dependent protein kinase kinase b (CaMKKb) activator ionomycin
(2 lM; OGD Iono) or the CaMKK inhibitor STO609 (10 lg/mL; OGD
STO). (a) Protein lysates were generated at the times shown and
assayed for AMPK activity. Significant differences were observed with
respect to treatment (a, p = 0.032) and time (b, p < 0.0001). The
presence of STO609 (open triangles) during the insult prevented the
activation of AMPK, whereas the presence of ionomycin (open
squares) increased the rate of activation of AMPK and its duration.
(b) Primary neurons were incubated for 2 h in the presence of DMSO
vehicle (Co; closed circles), ionomycin (2 lM; open squares) or
STO609 (10 lg/mL; open triangles) and cell death measured (using
release of lactate dehydrogenase (LDH) into the medium as a
surrogate). The LDH measurements shown represent normalized
absorbance at 450 nm. No significant differences were observed
between the groups (n = 6–7) (c). OGD resulted in a significant
increase in LDH production (open circles) compared with control
(closed circles), which was further exacerbated in the presence of
ionomycin (open squares). Conversely, the presence of STO609
(open triangles) significantly decreased the deleterious effect of the
insult on neurons (*p < 0.05, **p < 0.01, ***p < 0.001; n = 11–12)
(d). Primary neurons were incubated for 2 h in the presence of 5-
aminoimidazole-4-carboxamide 1-b-D-ribofuranoside (AICAR) and cell
death assessed as previously. No significant differences were
observed between vehicle- and AICAR-treated cells (n = 3). (e) As
stated earlier, OGD resulted in a significant increase in LDH
production (open circles) compared with control (closed circles). In
line with the previous observation with ionomycin, AICAR-treated
neurons appeared to produce more LDH, but this did not reach
significance (n = 7, **p < 0.01).
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with injury and we also see an increase in apoptosis in
primary neurons.
In rodent MCAO models of adult stroke, genetic ablation
of AMPKa2 reduces infarct volume. In contrast, we find that
it is AMPKa1 complexes that are critical in our insult model.
However, there are a growing number of studies suggesting
differential roles for AMPKa1 and AMPKa2, with AMPKa1
pathways more consistently linked with alteration in intra-
cellular calcium and therefore modulated by CaMKKb
(Stahmann et al. 2006; Tamas et al. 2006; Thornton et al.
2011). Recently, two independent studies identified a
hypoxia-mediated CaMKKb-AMPKa1 pathway triggered
in response to calcium release-activated calcium channels
(Gusarova et al. 2011; Mungai et al. 2011). Interestingly,
this mechanism was pathological in nature as AMPKa1
activation resulted in down-regulation of Na,K-ATPase and
subsequent lung dysfunction (Gusarova et al. 2011).
Several studies recently reported a protective role for
AMPK during preconditioning. Ischaemic preconditioning
was induced in adult rats by transient MCAO which up-
regulated AMPK activity and promoted autophagy. These
animals showed reduced infarct volume and improved
neurological function after a subsequent permanent MCAO
compared with rats in which AMPK or autophagy had been
inhibited (Jiang et al. 2014b). The same group showed that
this beneficial preconditioning could also be achieved by a
single dose of the AMPK activator, Metformin (Jiang et al.
2014a). However, this contradicts previous studies of brief
MCAO preconditioning where it was the significant inhibi-
tion of AMPK activity which provided protection (Venna
et al. 2012). In addition, preconditioning experiments in
primary neurons using the AMPK activator AICAR found
that the activation of AMPK was protective in a paradigm of
NMDA-induced excitotoxicity (Anilkumar et al. 2013).
Although our experiments targeted the Ca2+- rather than
the AMP/ADP-mediated activation of AMPK, our findings
are also consistent with a protective role for AMPK activity
in preconditioning. Depletion of AMPK prior to insult
significantly increased cell death, suggesting that the cells
were sensitized to the injury. Analysis of AMPK mRNA
levels after a recovery period suggested that they were
unaffected by prolonged pre-treatment with STO609 or
ionomycin. It is interesting to speculate therefore that it is the
metabolic maintenance role which AMPK performs in
continuously balancing the physiological energy demands
of the cell, which is critical.
****
***
+ OGD
(c)
(a) (b)
**
+ OGD
C
el
l d
ea
th
 (L
D
H
)
C
el
l d
ea
th
 (L
D
H
)
Fig. 5 Pharmacological inhibition of AMPK prior to oxygen–glucose
deprivation (OGD) sensitizes neurons to subsequent insult. (a)
Primary neurons were incubated in the presence of vehicle,
ionomycin or STO609, allowed to recover for 3 h in complete
medium and then subjected to OGD. A significant increase in lactate
dehydrogenase (LDH) release suggesting cell death post insult was
observed in cultures which had been treated with STO609 (open
triangles) compared with OGD alone (open circles). There was a
slight protective effect of ionomycin (open squares) but this did not
reach significance (***p < 0.001, ****p < 0.0001; n = 11–15). (b)
The experiment outlined in (a) was repeated leaving an interval of
24 h between pre-treatment and OGD. However, although the trend
was the same, the effects of ionomycin and STO609 were not
significant. (c) Primary neurons were treated with ionomycin and
STO609 as previously and allowed to recover for 3 or 24 h.
RNA was prepared from the cells and the expression of AMPKa1
(left panel) and AMPKa2 (right panel) determined by qRT-PCR.
There was no significant difference in AMPK mRNA expression
observed between treated samples and control at either 3 or 24 h
(n = 4).
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In contrast with the many physiological and pathological
activators of AMPK, there are very few cases in which
AMPK activity is inhibited in vivo and therefore sensitizing
neurons by AMPK depletion may represent the first stage in
a unique pathological cascade. One published inhibitor of
AMPK activity in vitro and in vivo is the endotoxin
lipopolysaccharide (LPS) derived from E. coli (Sag et al.
2008; Yang et al. 2010; Zhang et al. 2010). In addition,
infection contributes to neuronal sensitization in response to
neonatal hypoxic–ischaemic injury (Eklind et al. 2001,
2005; Hagberg and Mallard 2005). Interestingly, although
it has been suggested that LPS-mediated inhibition of AMPK
mainly occurs in macrophages rather than neurons, it is the
AMPKa1 complexes which are most affected (Sag et al.
2008; Yang et al. 2010). It is therefore tempting to speculate
that infection-mediated inhibition of AMPK sensitizes neu-
rons and other neural cells to HI-mediated injury (Fig. 6)
particularly as recent studies suggest that neurons may
possess the necessary components to sense bacterial infec-
tion, thus acting as a trigger for innate immunity signalling
(Liu et al. 2014). Indeed, LPS inhibition of AMPK expres-
sion in vivo is not limited to adult tissue as a very recent
paper described the same phenomenon in weaned piglets
(Kang et al. 2014) and we ourselves find a rapid decrease in
AMPKa1 and AMPKa2 mRNA expression in response to
LPS in neonatal rats (Hagberg H, unpublished data).
In conclusion, we find that AMPK is rapidly activated in a
mouse model of HI; replicating this injury in vitro, we show
that it is mediated by CaMKKb activation of AMPKa1
complexes. This aberrant AMPK activity during the insult
period may act to exacerbate injury as conversely, AMPK
inhibition reduces cell death. However, AMPK inhibition
prior to injury sensitizes neurons to OGD stress. Further
studies are required to determine whether bacterial inhibition
of AMPK prior to HI results in a worse outcome in mouse
models of HI and in neonatal HIE, and the molecular
mechanisms are still to be examined in detail.
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Fig. 6 AMPK activation offers a dual target
in the prevention of neuronal cell death.
Based on our data, we hypothesize that
prolonged activation of AMPK in neurons
and animal models of hypoxia–ischaemia
(HI) is deleterious suggesting that
pharmacological inhibition of AMPK activity
during the acute injury would be beneficial
(a). Conversely, exposure of the neuron to
pathological inhibitors of AMPK, as might
occur in the presence of a bacterial
infection, would render it more sensitive to
a subsequent insult (b).
© 2015 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
The International Society for Neurochemistry, J. Neurochem. (2015) 133, 242--252
250 C. I. Rousset et al.
Figure S1. Extent of injury in the Vannucci hypoxic–ischaemic
mouse model.
Figure S2. Comparison of the mRNA expression of AMPKa1
and AMPKa2 in primary neurons Total mRNA was extracted from
wild-type primary neurons and analysed by one-step qRT-PCR for
the expression of AMPK catalytic subunits.
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